Journal Article
. 2018 Aug; 50(9):1271-1281.
doi: 10.1038/s41588-018-0200-2.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

Diana Miao 1 Claire A Margolis 1 Natalie I Vokes 1 David Liu 1 Amaro Taylor-Weiner 1 Stephanie M Wankowicz 1 Dennis Adeegbe 2 Daniel Keliher 1 Bastian Schilling 3 Adam Tracy 4 Michael Manos 1 Nicole G Chau 1 Glenn J Hanna 1 Paz Polak 4 Scott J Rodig 1 Sabina Signoretti 1 Lynette M Sholl 1 Jeffrey A Engelman 5 Gad Getz 4 Pasi A Jänne 1 Robert I Haddad 1 Toni K Choueiri 1 David A Barbie 1 Rizwan Haq 1 Mark M Awad 1 Dirk Schadendorf 1 F Stephen Hodi 1 Joaquim Bellmunt 1 Kwok-Kin Wong 1 Peter Hammerman 1 Eliezer M Van Allen 6 
Affiliations
  • PMID: 30150660
  •     61 References
  •     172 citations

Abstract

Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we uniformly analyzed whole-exome sequencing (WES) of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy, including radiographic response, across multiple cancer types to examine additional tumor genomic features that contribute to selective response. Our analyses identified genomic correlates of response beyond mutational burden, including somatic events in individual driver genes, certain global mutational signatures, and specific HLA-restricted neoantigens. However, these features were often interrelated, highlighting the complexity of identifying genetic driver events that generate an immunoresponsive tumor environment. This study lays a path forward in analyzing large clinical cohorts in an integrated and multifaceted manner to enhance the ability to discover clinically meaningful predictive features of response to immune checkpoint blockade.

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Deng Pan, Aya Kobayashi, +13 authors, Kai W Wucherpfennig.
Science, 2018 Jan 06; 359(6377). PMID: 29301958    Free PMC article.
Highly Cited.
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.
Leandro M Colli, Mitchell J Machiela, +3 authors, Stephen J Chanock.
Cancer Res, 2016 May 20; 76(13). PMID: 27197178    Free PMC article.
Highly Cited.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation.
Maura Costello, Trevor J Pugh, +12 authors, Gad Getz.
Nucleic Acids Res, 2013 Jan 11; 41(6). PMID: 23303777    Free PMC article.
Highly Cited.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
Circular binary segmentation for the analysis of array-based DNA copy number data.
Adam B Olshen, E S Venkatraman, Robert Lucito, Michael Wigler.
Biostatistics, 2004 Oct 12; 5(4). PMID: 15475419
Highly Cited.
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Suzanne George, Diana Miao, +13 authors, Eliezer M Van Allen.
Immunity, 2017 Feb 24; 46(2). PMID: 28228279    Free PMC article.
Highly Cited.
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Eliezer M Van Allen, Hadrien G Golay, +27 authors, David A Barbie.
Cancer Immunol Res, 2015 May 28; 3(8). PMID: 26014096    Free PMC article.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
NetMHCpan, a method for MHC class I binding prediction beyond humans.
Ilka Hoof, Bjoern Peters, +5 authors, Morten Nielsen.
Immunogenetics, 2008 Nov 13; 61(1). PMID: 19002680    Free PMC article.
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Ramaswamy Govindan, Li Ding, +18 authors, Richard K Wilson.
Cell, 2012 Sep 18; 150(6). PMID: 22980976    Free PMC article.
Highly Cited.
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Stephen Henderson, Ankur Chakravarthy, +2 authors, Tim Robert Fenton.
Cell Rep, 2014 Jun 10; 7(6). PMID: 24910434
Highly Cited.
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Diana Miao, Claire A Margolis, +23 authors, Eliezer M Van Allen.
Science, 2018 Jan 06; 359(6377). PMID: 29301960    Free PMC article.
Highly Cited.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
Priscilla K Brastianos, Scott L Carter, +41 authors, William C Hahn.
Cancer Discov, 2015 Sep 28; 5(11). PMID: 26410082    Free PMC article.
Highly Cited.
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.
Courtney Hodges, Jacob G Kirkland, Gerald R Crabtree.
Cold Spring Harb Perspect Med, 2016 Jul 15; 6(8). PMID: 27413115    Free PMC article.
Highly Cited. Review.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Moshe Sade-Feldman, Yunxin J Jiao, +28 authors, Nir Hacohen.
Nat Commun, 2017 Oct 27; 8(1). PMID: 29070816    Free PMC article.
Highly Cited.
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
Stephanie A Mullane, Lillian Werner, +5 authors, Joaquim Bellmunt.
Sci Rep, 2016 Jun 11; 6. PMID: 27283319    Free PMC article.
Absolute quantification of somatic DNA alterations in human cancer.
Scott L Carter, Kristian Cibulskis, +13 authors, Gad Getz.
Nat Biotechnol, 2012 May 01; 30(5). PMID: 22544022    Free PMC article.
Highly Cited.
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Kent W Mouw, James M Cleary, +16 authors, Alan D D'Andrea.
Clin Cancer Res, 2016 Nov 18; 23(12). PMID: 27852700    Free PMC article.
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
Kristian Cibulskis, Michael S Lawrence, +7 authors, Gad Getz.
Nat Biotechnol, 2013 Feb 12; 31(3). PMID: 23396013    Free PMC article.
Highly Cited.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Mariam Jamal-Hanjani, Gareth A Wilson, +81 authors, TRACERx Consortium.
N Engl J Med, 2017 Apr 27; 376(22). PMID: 28445112
Highly Cited.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Scott Gettinger, Naiyer A Rizvi, +13 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354485    Free PMC article.
Highly Cited.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, +32 authors, Luis A Diaz.
N Engl J Med, 2015 Jun 02; 372(26). PMID: 26028255    Free PMC article.
Highly Cited.
An immunogenic personal neoantigen vaccine for patients with melanoma.
Patrick A Ott, Zhuting Hu, +37 authors, Catherine J Wu.
Nature, 2017 Jul 06; 547(7662). PMID: 28678778    Free PMC article.
Highly Cited.
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence.
Morten Nielsen, Claus Lundegaard, +8 authors, Søren Buus.
PLoS One, 2007 Aug 30; 2(8). PMID: 17726526    Free PMC article.
Highly Cited.
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
Eliezer M Van Allen, Nikhil Wagle, +33 authors, Levi A Garraway.
Nat Med, 2014 May 20; 20(6). PMID: 24836576    Free PMC article.
Highly Cited.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, +47 authors, Özlem Türeci.
Nature, 2017 Jul 06; 547(7662). PMID: 28678784
Highly Cited.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.
Nadeem Riaz, Jonathan J Havel, +5 authors, Timothy A Chan.
Nat Genet, 2016 Oct 28; 48(11). PMID: 27668655    Free PMC article.
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
Teresa Davoli, Hajime Uno, Eric C Wooten, Stephen J Elledge.
Science, 2017 Jan 21; 355(6322). PMID: 28104840    Free PMC article.
Highly Cited.
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.
Sachet A Shukla, Michael S Rooney, +14 authors, Gad Getz.
Nat Biotechnol, 2015 Sep 16; 33(11). PMID: 26372948    Free PMC article.
Highly Cited.
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.
Jianjiong Gao, Matthew T Chang, +8 authors, Chris Sander.
Genome Med, 2017 Jan 25; 9(1). PMID: 28115009    Free PMC article.
Highly Cited.
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Jaegil Kim, Kent W Mouw, +7 authors, Gad Getz.
Nat Genet, 2016 Apr 26; 48(6). PMID: 27111033    Free PMC article.
Highly Cited.
Comprehensive molecular characterization of urothelial bladder carcinoma.
Cancer Genome Atlas Research Network.
Nature, 2014 Jan 31; 507(7492). PMID: 24476821    Free PMC article.
Highly Cited.
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, +12 authors, Nikolaus Schultz.
Cancer Discov, 2012 May 17; 2(5). PMID: 22588877    Free PMC article.
Highly Cited.
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
Shumei Kato, Aaron Goodman, +3 authors, Razelle Kurzrock.
Clin Cancer Res, 2017 Mar 30; 23(15). PMID: 28351930    Free PMC article.
Highly Cited.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, +33 authors, Charles Swanton.
Science, 2016 Mar 05; 351(6280). PMID: 26940869    Free PMC article.
Highly Cited.
ContEst: estimating cross-contamination of human samples in next-generation sequencing data.
Kristian Cibulskis, Aaron McKenna, +3 authors, Gad Getz.
Bioinformatics, 2011 Aug 02; 27(18). PMID: 21803805    Free PMC article.
Highly Cited.
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Antje Sucker, Fang Zhao, +20 authors, Annette Paschen.
Nat Commun, 2017 Jun 01; 8. PMID: 28561041    Free PMC article.
Highly Cited.
CDK4/6 inhibition triggers anti-tumour immunity.
Shom Goel, Molly J DeCristo, +17 authors, Jean J Zhao.
Nature, 2017 Aug 17; 548(7668). PMID: 28813415    Free PMC article.
Highly Cited.
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Andrea Garofalo, Lynette Sholl, +18 authors, Eliezer M Van Allen.
Genome Med, 2016 Jul 28; 8(1). PMID: 27460824    Free PMC article.
Highly Cited.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, +37 authors, P Andrew Futreal.
Sci Transl Med, 2017 Mar 03; 9(379). PMID: 28251903    Free PMC article.
Highly Cited.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, +41 authors, Patrick Hwu.
Cancer Discov, 2015 Dec 10; 6(2). PMID: 26645196    Free PMC article.
Highly Cited.
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, +10 authors, Nikolaus Schultz.
Sci Signal, 2013 Apr 04; 6(269). PMID: 23550210    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, +29 authors, Matthew D Hellmann.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29337640    Free PMC article.
Highly Cited.
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.
Douglas B Johnson, Christine M Lovly, +12 authors, Jeffrey A Sosman.
Cancer Immunol Res, 2015 Mar 05; 3(3). PMID: 25736262    Free PMC article.
Highly Cited.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
Review.
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.
Christopher T Saunders, Wendy S W Wong, +3 authors, R Keira Cheetham.
Bioinformatics, 2012 May 15; 28(14). PMID: 22581179
Highly Cited.
NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets.
Morten Nielsen, Massimo Andreatta.
Genome Med, 2016 Apr 01; 8(1). PMID: 27029192    Free PMC article.
Highly Cited.
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
Elza C de Bruin, Nicholas McGranahan, +40 authors, Charles Swanton.
Science, 2014 Oct 11; 346(6206). PMID: 25301630    Free PMC article.
Highly Cited.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin, Sara Pilotto, +11 authors, Giampaolo Tortora.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086854    Free PMC article.
Highly Cited.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, +13 authors, Padmanee Sharma.
Cell, 2016 Sep 27; 167(2). PMID: 27667683    Free PMC article.
Highly Cited.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
Jake R Conway, Eric Kofman, +2 authors, Eliezer Van Allen.
Genome Med, 2018 Dec 01; 10(1). PMID: 30497521    Free PMC article.
Review.
Pan-cancer analysis connects tumor matrisome to immune response.
Su Bin Lim, Melvin Lee Kiang Chua, +3 authors, Chwee Teck Lim.
NPJ Precis Oncol, 2019 May 28; 3. PMID: 31123708    Free PMC article.
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Aaron M Goodman, Ethan S Sokol, +2 authors, Razelle Kurzrock.
Cancer Immunol Res, 2019 Aug 14; 7(10). PMID: 31405947    Free PMC article.
Panel-based estimates of tumor mutational burden: characterizing unknown unknowns.
W Yang, L G T Morris, T A Chan.
Ann Oncol, 2019 Aug 15; 30(9). PMID: 31410441    Free PMC article.
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy.
Shixiang Wang, Li An Cowley, Xue-Song Liu.
Molecules, 2019 Sep 07; 24(18). PMID: 31487832    Free PMC article.
Highly Cited. Review.
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.
Yochai Wolf, Osnat Bartok, +26 authors, Yardena Samuels.
Cell, 2019 Sep 17; 179(1). PMID: 31522890    Free PMC article.
Highly Cited.
Current Perspectives in Cancer Immunotherapy.
Theodoulakis Christofi, Stavroula Baritaki, +2 authors, Apostolos Zaravinos.
Cancers (Basel), 2019 Oct 03; 11(10). PMID: 31575023    Free PMC article.
Review.
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Kroopa Joshi, Marc Robert de Massy, +32 authors, Benny Chain.
Nat Med, 2019 Oct 09; 25(10). PMID: 31591606    Free PMC article.
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Hao-Xiang Wu, Yan-Xing Chen, +5 authors, Rui-Hua Xu.
J Immunother Cancer, 2019 Oct 19; 7(1). PMID: 31623662    Free PMC article.
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy.
Rik G H Lindeboom, Michiel Vermeulen, Ben Lehner, Fran Supek.
Nat Genet, 2019 Oct 30; 51(11). PMID: 31659324    Free PMC article.
Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.
Ramy R Saleh, Paloma Peinado, +4 authors, Alberto Ocaña.
Front Oncol, 2019 Nov 05; 9. PMID: 31681578    Free PMC article.
Systematic Review.
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.
Jianzhen Lin, Kun Dong, +14 authors, Haitao Zhao.
Ann Transl Med, 2019 Nov 09; 7(18). PMID: 31700903    Free PMC article.
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Shixiang Wang, Zaoke He, +2 authors, Xue-Song Liu.
Elife, 2019 Nov 27; 8. PMID: 31767055    Free PMC article.
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Andreas Kronbichler, +5 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 17; 11(11). PMID: 31731749    Free PMC article.
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
Natalie I Vokes, David Liu, +19 authors, Mark M Awad.
JCO Precis Oncol, 2019 Dec 14; 3. PMID: 31832578    Free PMC article.
Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes.
Tao Jiang, Xiaoxia Chen, +2 authors, Caicun Zhou.
J Cancer, 2020 Jan 18; 11(4). PMID: 31949479    Free PMC article.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Samuel J Klempner, David Fabrizio, +8 authors, Prasanth Reddy.
Oncologist, 2019 Oct 04; 25(1). PMID: 31578273    Free PMC article.
Review.
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Sadal Refae, Jocelyn Gal, +7 authors, Esma Saada-Bouzid.
Invest New Drugs, 2019 Aug 14; 38(1). PMID: 31402427
High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy.
Angela Mauriello, Roberta Zeuli, +6 authors, Luigi Buonaguro.
Cancers (Basel), 2019 Nov 24; 11(12). PMID: 31756926    Free PMC article.
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
Caroline A Nebhan, Douglas B Johnson.
Expert Rev Anticancer Ther, 2020 Jan 31; 20(2). PMID: 31997676    Free PMC article.
Review.
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Saori Mishima, Akihito Kawazoe, +11 authors, Kohei Shitara.
J Immunother Cancer, 2019 Feb 02; 7(1). PMID: 30704511    Free PMC article.
Highly Cited.
Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen.
Nat Med, 2019 Mar 08; 25(3). PMID: 30842677    Free PMC article.
Highly Cited. Review.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
David Liu, Bastian Schilling, +33 authors, Dirk Schadendorf.
Nat Med, 2019 Dec 04; 25(12). PMID: 31792460    Free PMC article.
Highly Cited.
A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
Wei Nie, Jie Qian, +15 authors, Bao-Hui Han.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158623    Free PMC article.
Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Jie Peng, Dan Zou, +2 authors, Lijie Han.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158626    Free PMC article.
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer.
Huaqiang Zhou, Jiaqing Liu, +5 authors, Li Zhang.
NPJ Precis Oncol, 2020 Mar 21; 4. PMID: 32195359    Free PMC article.
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.
Ya-Ru Miao, Qiong Zhang, +4 authors, An-Yuan Guo.
Adv Sci (Weinh), 2020 Apr 11; 7(7). PMID: 32274301    Free PMC article.
Sex-associated molecular differences for cancer immunotherapy.
Youqiong Ye, Ying Jing, +4 authors, Leng Han.
Nat Commun, 2020 Apr 15; 11(1). PMID: 32286310    Free PMC article.
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Laurent Mhanna, Nicolas Guibert, Julie Milia, Julien Mazieres.
Curr Treat Options Oncol, 2019 Jun 07; 20(7). PMID: 31172347    Free PMC article.
Review.
Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Tomoyuki Naito, Shigeki Umemura, +11 authors, Koichi Goto.
Thorac Cancer, 2019 Apr 12; 10(5). PMID: 30972962    Free PMC article.
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, +18 authors, Erica L Carpenter.
Clin Cancer Res, 2020 Feb 28; 26(10). PMID: 32102950    Free PMC article.
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
Hoi-Lam Ngan, Yuchen Liu, +15 authors, Vivian Wai Yan Lui.
Life Sci Alliance, 2020 May 10; 3(6). PMID: 32381551    Free PMC article.
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Tianshi Lu, Shidan Wang, +11 authors, Tao Wang.
Sci Immunol, 2020 Feb 23; 5(44). PMID: 32086382    Free PMC article.
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
Qingzhu Jia, Jun Wang, +2 authors, Bo Zhu.
JCI Insight, 2019 May 17; 4(10). PMID: 31092729    Free PMC article.
Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma.
Zhen Zhang, Jinyan Liu, +7 authors, Yi Zhang.
Front Cell Dev Biol, 2020 Jun 09; 8. PMID: 32509772    Free PMC article.
Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.
Wenfeng Fang, Yuxiang Ma, +11 authors, Li Zhang.
Clin Transl Med, 2020 Jun 09; 10(1). PMID: 32508057    Free PMC article.
Clinical implications of mismatch repair deficiency in prostate cancer.
Ramy Sedhom, Emmanuel S Antonarakis.
Future Oncol, 2019 Jun 27; 15(20). PMID: 31237441    Free PMC article.
Review.
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai, De-Hua Wu, +11 authors, Zhong-Yi Dong.
J Immunother Cancer, 2020 Jul 02; 8(1). PMID: 32606052    Free PMC article.
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden.
David Hsiehchen, Antony Hsieh, +6 authors, Hao Zhu.
Cell Rep Med, 2020 Jul 18; 1(3). PMID: 32676589    Free PMC article.
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Sarah Abou Alaiwi, Amin H Nassar, +29 authors, Toni K Choueiri.
Cancer Immunol Res, 2020 Apr 24; 8(8). PMID: 32321774    Free PMC article.
Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment.
Xinyi Wang, Jinzhong Duanmu, +2 authors, Qunguang Jiang.
J Transl Med, 2020 Aug 30; 18(1). PMID: 32859214    Free PMC article.
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
A Ari Hakimi, Kyrollis Attalla, +14 authors, Robert J Motzer.
Nat Commun, 2020 Aug 21; 11(1). PMID: 32820162    Free PMC article.
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Lei Zhang, Xiaohong Han, Yuankai Shi.
JAMA Netw Open, 2020 Aug 28; 3(8). PMID: 32845327    Free PMC article.
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.
Michael Bitzer, Leonie Ostermann, +15 authors, Nisar P Malek.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923905    Free PMC article.
Review.
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.
Maria Eugenia Gallo Cantafio, Katia Grillone, +6 authors, Maria Teresa Di Martino.
High Throughput, 2018 Oct 31; 7(4). PMID: 30373182    Free PMC article.
Review.
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.
Léa Berland, Simon Heeke, +11 authors, Marius Ilié.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775030    Free PMC article.
Review.
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity.
Andréa E Tijhuis, Sarah C Johnson, Sarah E McClelland.
Mol Cytogenet, 2019 May 23; 12. PMID: 31114634    Free PMC article.
Review.
MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer.
Yue Yang, Jieyun Zhang, +3 authors, Weijian Guo.
Clin Transl Med, 2020 Sep 09; 10(4). PMID: 32898332    Free PMC article.
New biomarkers for checkpoint inhibitor therapy.
Nikki Burdett, Jayesh Desai.
ESMO Open, 2020 Sep 17; 5(Suppl 1). PMID: 32933940    Free PMC article.
Review.
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Yusuke Inoue, Katsuhiro Yoshimura, +24 authors, Takafumi Suda.
JAMA Netw Open, 2020 Sep 22; 3(9). PMID: 32955570    Free PMC article.
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
Valsamo Anagnostou, Noushin Niknafs, +32 authors, Victor E Velculescu.
Nat Cancer, 2020 Sep 29; 1(1). PMID: 32984843    Free PMC article.
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.
Xingwu Zhou, Moyuan Qu, +9 authors, Ali Khademhosseini.
Adv Sci (Weinh), 2020 Oct 13; 7(19). PMID: 33042756    Free PMC article.
Review.
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Tae Hee Hong, Hongui Cha, +17 authors, Woong-Yang Park.
J Immunother Cancer, 2020 Oct 21; 8(2). PMID: 33077514    Free PMC article.
Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma.
Paul J Bröckelmann, Mathilde R W de Jong, Ron D Jachimowicz.
Cells, 2020 Oct 18; 9(10). PMID: 33066395    Free PMC article.
Review.
Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival.
Yanmei Gao, Chunhe Yang, +3 authors, Yadong Yang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194669    Free PMC article.
Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Junjie Jiang, Yongfeng Ding, +5 authors, Lisong Teng.
Cancer Med, 2020 Sep 25; 9(22). PMID: 32969604    Free PMC article.
Systematic Review.
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.
S Derks, L K de Klerk, +17 authors, A J Bass.
Ann Oncol, 2020 May 11; 31(8). PMID: 32387455    Free PMC article.
Breast Cancer Heterogeneity and Response to Novel Therapeutics.
Mariona Baliu-Piqué, Atanasio Pandiella, Alberto Ocana.
Cancers (Basel), 2020 Nov 11; 12(11). PMID: 33167363    Free PMC article.
Review.
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Guangchuan Wang, Ryan D Chow, +16 authors, Sidi Chen.
Cancer Discov, 2020 Sep 06; 10(12). PMID: 32887696    Free PMC article.
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Dan Sha, Zhaohui Jin, +3 authors, Frank A Sinicrope.
Cancer Discov, 2020 Nov 04; 10(12). PMID: 33139244    Free PMC article.
Integrated molecular drivers coordinate biological and clinical states in melanoma.
Jake R Conway, Felix Dietlein, +13 authors, Eliezer M Van Allen.
Nat Genet, 2020 Nov 25; 52(12). PMID: 33230298    Free PMC article.
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Siwen Hu-Lieskovan, Srabani Bhaumik, +14 authors, Holden T Maecker.
J Immunother Cancer, 2020 Dec 04; 8(2). PMID: 33268350    Free PMC article.
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Hua Bai, Jianchun Duan, +14 authors, Zhijie Wang.
J Immunother Cancer, 2020 Dec 12; 8(2). PMID: 33303576    Free PMC article.
Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Xia Ran, Jinyuan Xiao, +5 authors, Zhongsheng Sun.
Ther Adv Med Oncol, 2021 Jan 12; 12. PMID: 33425025    Free PMC article.
Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Quanwei Zhou, Xuejun Yan, +5 authors, Caiping Ren.
Front Oncol, 2021 Jan 12; 10. PMID: 33425739    Free PMC article.
Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling.
Hao Jiang, Jing-Yuan Tang, +4 authors, Xiao-Zhou He.
Cancer Cell Int, 2021 Jan 13; 21(1). PMID: 33430855    Free PMC article.
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Eryn Blass, Patrick A Ott.
Nat Rev Clin Oncol, 2021 Jan 22; 18(4). PMID: 33473220    Free PMC article.
Review.
Whole-genome doubling confers unique genetic vulnerabilities on tumour cells.
Ryan J Quinton, Amanda DiDomizio, +12 authors, Neil J Ganem.
Nature, 2021 Jan 29; 590(7846). PMID: 33505027    Free PMC article.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Jianjun Gao, Neema Navai, +28 authors, Padmanee Sharma.
Nat Med, 2020 Oct 14; 26(12). PMID: 33046869
Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Esther Coronado, Yania Yañez, +8 authors, Jaime Font de Mora.
Mol Oncol, 2020 Dec 01; 15(2). PMID: 33252831    Free PMC article.
KRAS mutations are negatively correlated with immunity in colon cancer.
Xiaorui Fu, Xinyi Wang, +2 authors, Qunguang Jiang.
Aging (Albany NY), 2020 Dec 01; 13(1). PMID: 33254149    Free PMC article.
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhen Zhang, Hao-Xiang Wu, +4 authors, Hui-Yan Luo.
BMC Med, 2021 Feb 03; 19(1). PMID: 33526018    Free PMC article.
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.
Wei Nie, Lu Gan, +17 authors, Bao-Hui Han.
Oncoimmunology, 2021 Feb 05; 10(1). PMID: 33537171    Free PMC article.
Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma.
Ping Tao, Liang Hong, +5 authors, Ruyi Xue.
Front Oncol, 2021 Feb 09; 10. PMID: 33552954    Free PMC article.
Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor.
Junjun He, Wei Ouyang, +8 authors, Wencai Li.
Ann Transl Med, 2021 Feb 12; 9(2). PMID: 33569431    Free PMC article.
Intratumoral heterogeneity in cancer progression and response to immunotherapy.
Ilio Vitale, Efrat Shema, Sherene Loi, Lorenzo Galluzzi.
Nat Med, 2021 Feb 13; 27(2). PMID: 33574607
Review.
Understanding adverse events of immunotherapy: A mechanistic perspective.
Kelly P Burke, Stephanie Grebinoski, Arlene H Sharpe, Dario A A Vignali.
J Exp Med, 2021 Feb 19; 218(1). PMID: 33601411    Free PMC article.
Review.
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Alvin P Makohon-Moore, Evan J Lipson, +19 authors, Christine A Iacobuzio-Donahue.
Clin Cancer Res, 2020 Dec 17; 27(5). PMID: 33323400    Free PMC article.
Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.
Peng Zhang, Yixuan Huang.
J Hematol Oncol, 2021 Mar 04; 14(1). PMID: 33653367    Free PMC article.
The Role of Real-Time Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Reninoma: Case Report and Literature Review.
Rui Zhang, Ming Xu, Xiao-Yan Xie.
Front Oncol, 2021 Mar 10; 11. PMID: 33686368    Free PMC article.
Personalized Immuno-Oncology.
Kewal K Jain.
Med Princ Pract, 2020 Aug 26; 30(1). PMID: 32841942    Free PMC article.
Review.
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
Kevin Litchfield, James L Reading, +25 authors, Charles Swanton.
Cell, 2021 Jan 29; 184(3). PMID: 33508232    Free PMC article.
Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy.
Sara De Biasi, Lara Gibellini, +16 authors, Andrea Cossarizza.
Nat Commun, 2021 Mar 17; 12(1). PMID: 33723257    Free PMC article.
Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
Tess A O'Meara, Sara M Tolaney.
Oncotarget, 2021 Mar 23; 12(5). PMID: 33747355    Free PMC article.
Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
A Rouf Banday, Olusegun O Onabajo, +10 authors, Ludmila Prokunina-Olsson.
Commun Biol, 2021 Mar 24; 4(1). PMID: 33753867    Free PMC article.
Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Alexandra M Haugh, April K S Salama, Douglas B Johnson.
Hematol Oncol Clin North Am, 2021 Mar 25; 35(1). PMID: 33759769    Free PMC article.
Review.
Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.
Anqi Lin, Zhengang Qiu, Jian Zhang, Peng Luo.
Front Immunol, 2021 Mar 26; 12. PMID: 33763074    Free PMC article.
[Tumor biology of oropharyngeal carcinoma].
S Laban, M Brand, +5 authors, T K Hoffmann.
HNO, 2020 Nov 21; 69(4). PMID: 33215226
Review.
Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Yuxiang Ma, Xi Chen, +12 authors, Li Zhang.
J Immunother Cancer, 2021 Mar 20; 9(3). PMID: 33737344    Free PMC article.
Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy.
Ajay Chatrath, Aakrosh Ratan, Anindya Dutta.
iScience, 2021 Apr 01; 24(3). PMID: 33786423    Free PMC article.
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
Quynh Thu Le, A Dimitrios Colevas, +9 authors, Shakun Malik.
J Natl Cancer Inst, 2019 Mar 27; 111(7). PMID: 30912808    Free PMC article.
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Joan Frigola, Alejandro Navarro, +17 authors, Ramon Amat.
Mol Oncol, 2020 Dec 21; 15(4). PMID: 33342055    Free PMC article.
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
D J McGrail, P G Pilié, +13 authors, S-Y Lin.
Ann Oncol, 2021 Mar 20; 32(5). PMID: 33736924    Free PMC article.
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Giovanni Melillo, Vikram Chand, +2 authors, Cristian Massacesi.
Adv Ther, 2021 Apr 22; 38(6). PMID: 33881745    Free PMC article.
Review.
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Ramon Gonzalez Manzano, Ana Catalan-Latorre, Antonio Brugarolas.
BMC Cancer, 2021 Apr 22; 21(1). PMID: 33879103    Free PMC article.
MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Lei Sun, Man Li, +4 authors, Linlang Guo.
Front Pharmacol, 2021 May 01; 12. PMID: 33927616    Free PMC article.
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer.
Maria Tello-Lafoz, Katja Srpan, +12 authors, Ekrem Emrah Er.
Immunity, 2021 Mar 24; 54(5). PMID: 33756102    Free PMC article.
Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.
Wenwen Guo, Caiqin Zhang, +2 authors, Changhong Shi.
Front Oncol, 2021 May 18; 11. PMID: 33996603    Free PMC article.
Review.
Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit.
Ayal B Gussow, Eugene V Koonin, Noam Auslander.
NAR Cancer, 2021 May 25; 3(2). PMID: 34027407    Free PMC article.
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
Leticia De Mattos-Arruda, Javier Cortes, +17 authors, Carlos Caldas.
NPJ Breast Cancer, 2021 Jun 09; 7(1). PMID: 34099718    Free PMC article.
Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma.
Haoxuan Ying, Anqi Lin, +2 authors, Peng Luo.
Front Mol Biosci, 2021 Jun 12; 8. PMID: 34113648    Free PMC article.
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Benjamin P Fairfax, Chelsea A Taylor, +12 authors, Mark R Middleton.
Nat Med, 2020 Feb 12; 26(2). PMID: 32042196    Free PMC article.
Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
Yang Wen, Anqi Lin, +4 authors, Jian Zhang.
Front Pharmacol, 2021 Jun 25; 12. PMID: 34163353    Free PMC article.
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy.
Mingdong Lu, Bin Zhao, +4 authors, Xian Shen.
NPJ Precis Oncol, 2021 Jun 16; 5(1). PMID: 34127768    Free PMC article.
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Libin Zhang, Yanhui Chen, +10 authors, Hao Peng.
J Immunother Cancer, 2021 Jun 19; 9(6). PMID: 34140315    Free PMC article.
Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Qianhui Xu, Hao Xu, +5 authors, Wen Huang.
Cancer Cell Int, 2021 Jul 05; 21(1). PMID: 34217320    Free PMC article.
Prognostic and immunological role of CD36: A pan-cancer analysis.
Yong-Jian Chen, Wei-Xin Liao, +7 authors, Xing Li.
J Cancer, 2021 Jul 09; 12(16). PMID: 34234847    Free PMC article.
Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
Junyu Long, Dongxu Wang, +8 authors, Haitao Zhao.
BMC Med, 2021 Jul 22; 19(1). PMID: 34284787    Free PMC article.
Emerging targets for anticancer vaccination: IDH.
M Platten, L Bunse, W Wick.
ESMO Open, 2021 Jul 17; 6(4). PMID: 34271312    Free PMC article.
Review.
The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Xiaohua Li, Yuntao Wang, +3 authors, Yifeng Bai.
Front Immunol, 2021 Jul 27; 12. PMID: 34305884    Free PMC article.
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Riyue Bao, Stefani Spranger, +7 authors, Ami V Desai.
J Immunother Cancer, 2021 Jul 18; 9(7). PMID: 34272305    Free PMC article.
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.
Kyrollis Attalla, Stanley Weng, Martin H Voss, A Ari Hakimi.
Urol Clin North Am, 2020 Jul 01; 47(3). PMID: 32600532    Free PMC article.
Review.
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Lynette M Sholl, Fred R Hirsch, +35 authors, John W Longshore.
J Thorac Oncol, 2020 Jun 12; 15(9). PMID: 32522712    Free PMC article.
Review.
TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Teng Li, Han Wang, +8 authors, Zhijie Wang.
Ther Adv Med Oncol, 2021 Aug 20; 13. PMID: 34408796    Free PMC article.
Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.
Yi-Hui Pan, Jia-Xing Zhang, +5 authors, Jun-Hang Luo.
Front Immunol, 2021 Aug 24; 12. PMID: 34421886    Free PMC article.
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
Romualdo Barroso-Sousa, Tanya E Keenan, +13 authors, Sara M Tolaney.
NPJ Breast Cancer, 2021 Aug 27; 7(1). PMID: 34433812    Free PMC article.
The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence.
Ichidai Tanaka, Taiki Furukawa, Masahiro Morise.
Cancer Cell Int, 2021 Aug 28; 21(1). PMID: 34446006    Free PMC article.
Review.
Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Zhe Wang, Chunguang Wang, Shengcheng Lin, Xin Yu.
Front Oncol, 2021 Sep 14; 11. PMID: 34513703    Free PMC article.
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Xinke Zhang, Yingying Wang, +2 authors, Jiewei Chen.
Front Immunol, 2021 Sep 18; 12. PMID: 34531868    Free PMC article.
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Tanya E Keenan, Jennifer L Guerriero, +26 authors, Sara M Tolaney.
Nat Commun, 2021 Sep 23; 12(1). PMID: 34548479    Free PMC article.
Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma.
Qianhui Xu, Shaohuai Chen, Yuanbo Hu, Wen Huang.
Front Genet, 2021 Oct 01; 12. PMID: 34589117    Free PMC article.
Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy.
Xiaobo Zheng, Yong Gao, +5 authors, Mingqing Xu.
Sci Rep, 2021 Oct 02; 11(1). PMID: 34593914    Free PMC article.
CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells.
Myung-Chul Kim, Nicholas Borcherding, +32 authors, Weizhou Zhang.
Nat Commun, 2021 Oct 03; 12(1). PMID: 34599187    Free PMC article.
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Yiting Sun, Jianchun Duan, +10 authors, Jie Wang.
BMC Med, 2021 Oct 08; 19(1). PMID: 34615542    Free PMC article.
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
Kyrollis Attalla, Renzo G DiNatale, +17 authors, A Ari Hakimi.
Clin Cancer Res, 2021 Jul 16; 27(20). PMID: 34261695    Free PMC article.
Weighted Gene Co-expression Network Analysis Identifies a Cancer-Associated Fibroblast Signature for Predicting Prognosis and Therapeutic Responses in Gastric Cancer.
Hang Zheng, Heshu Liu, +2 authors, Xin Wang.
Front Mol Biosci, 2021 Oct 26; 8. PMID: 34692770    Free PMC article.
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Diego Chowell, Seong-Keun Yoo, +31 authors, Timothy A Chan.
Nat Biotechnol, 2021 Nov 03; 40(4). PMID: 34725502
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response.
Yosuke Sato, Yu Fu, +2 authors, Michael H Shaw.
BMC Cancer, 2021 Nov 15; 21(1). PMID: 34774008    Free PMC article.
Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
Fuyan Shi, Wenjing Zhang, +6 authors, Qinghua Wang.
Front Immunol, 2021 Nov 20; 12. PMID: 34795662    Free PMC article.
Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
Qi Yang, Hongman Zhang, +4 authors, Jian Zhang.
Front Immunol, 2021 Nov 23; 12. PMID: 34804043    Free PMC article.
Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor.
Marcello Moro Queiroz, Zenaide Silva de Souza, +8 authors, Diogo Assed Bastos.
Ecancermedicalscience, 2021 Nov 27; 15. PMID: 34824629    Free PMC article.
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer.
Miruna Grecea, Olga Soritau, +2 authors, Mihnea Zdrenghea.
Onco Targets Ther, 2021 Dec 02; 14. PMID: 34848970    Free PMC article.
Review.
Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ying-Peng Peng, Rong Wang, +5 authors, Zhi-Gang Liu.
Front Genet, 2021 Dec 07; 12. PMID: 34868231    Free PMC article.
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types.
Zhe Gong, Yue Yang, Jieyun Zhang, Weijian Guo.
Cancer Biol Med, 2021 May 08;. PMID: 33960179    Free PMC article.
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Lingling Zhu, Jiewei Liu, Jiang Chen, Qinghua Zhou.
J Hematol Oncol, 2021 Dec 22; 14(1). PMID: 34930377    Free PMC article.
Review.
Cell cycle on the crossroad of tumorigenesis and cancer therapy.
Jing Liu, Yunhua Peng, Wenyi Wei.
Trends Cell Biol, 2021 Jul 27; 32(1). PMID: 34304958    Free PMC article.
Review.
Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
Yanni Xiao, Di Lu, +11 authors, Li Yang.
Ann Transl Med, 2022 Jan 07; 9(22). PMID: 34988170    Free PMC article.
Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.
Chia-Chin Wu, Y Alan Wang, +2 authors, P Andrew Futreal.
Nat Commun, 2022 Jan 12; 13(1). PMID: 35013211    Free PMC article.
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
Fang Yang, Jacqueline F Wang, +2 authors, Julian R Molina.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008273    Free PMC article.
Review.
SNF5, a core subunit of SWI/SNF complex, regulates melanoma cancer cell growth, metastasis, and immune escape in response to matrix stiffness.
Ying Chen, Meilian Zhao, +4 authors, Liling Tang.
Transl Oncol, 2022 Jan 10; 17. PMID: 34999540    Free PMC article.
Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Yong Liu, Guangbing Li, +4 authors, Jun Liu.
Front Genet, 2022 Jan 21; 12. PMID: 35046996    Free PMC article.
Biomarkers for predicting the efficacy of immune checkpoint inhibitors.
Chengji Wang, He-Nan Wang, Liang Wang.
J Cancer, 2022 Jan 25; 13(2). PMID: 35069896    Free PMC article.
Review.
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Wenjing Zhang, Yujia Kong, +5 authors, Qinghua Wang.
Front Immunol, 2022 Jan 29; 12. PMID: 35087523    Free PMC article.
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade.
Cécile Gstalder, David Liu, +21 authors, Rizwan Haq.
Cancer Discov, 2020 May 07; 10(9). PMID: 32371478    Free PMC article.
Identification of neoantigens for individualized therapeutic cancer vaccines.
Franziska Lang, Barbara Schrörs, +2 authors, Ugur Sahin.
Nat Rev Drug Discov, 2022 Feb 03; 21(4). PMID: 35105974    Free PMC article.
Review.
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC.
Fan Zhang, Jinliang Wang, +6 authors, Yi Hu.
NPJ Precis Oncol, 2022 Jan 20; 6(1). PMID: 35042953    Free PMC article.
Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.
Yosuke Miura, Norimitsu Kasahara, Noriaki Sunaga.
Transl Cancer Res, 2019 Dec 01; 8(Suppl 6). PMID: 35117146    Free PMC article.
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.
Amy L Cummings, Jaklin Gukasyan, +18 authors, Edward B Garon.
Nat Cancer, 2020 Dec 01; 1(12). PMID: 35121931
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.
Rached Alkallas, Mathieu Lajoie, +9 authors, Ian R Watson.
Nat Cancer, 2020 Jun 01; 1(6). PMID: 35121978    Free PMC article.
Genomics-guided pre-clinical development of cancer therapies.
Hayley E Francies, Ultan McDermott, Mathew J Garnett.
Nat Cancer, 2020 May 01; 1(5). PMID: 35121986
Review.
Discovery through clinical sequencing in oncology.
Mark T A Donoghue, Alison M Schram, David M Hyman, Barry S Taylor.
Nat Cancer, 2020 Aug 01; 1(8). PMID: 35122052    Free PMC article.
Review.
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Wenjing Zhang, Fuyan Shi, +4 authors, Qinghua Wang.
Cancer Med, 2021 Dec 05; 11(3). PMID: 34862763    Free PMC article.
A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Junyu Long, Dongxu Wang, +9 authors, Haitao Zhao.
Genome Med, 2022 Feb 25; 14(1). PMID: 35197093    Free PMC article.
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Zhenxing Feng, Yan Yin, +4 authors, Jianwen Qin.
Cancer Control, 2022 Feb 26; 29. PMID: 35212236    Free PMC article.
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Samuel S Freeman, Moshe Sade-Feldman, +36 authors, Nir Hacohen.
Cell Rep Med, 2022 Mar 05; 3(2). PMID: 35243413    Free PMC article.
PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival.
Daniela Cochicho, Susana Esteves, +7 authors, Ana Felix.
Cancers (Basel), 2022 Mar 11; 14(5). PMID: 35267596    Free PMC article.
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
Deqiang Wang, Xiaofeng Chen, +9 authors, Yongqian Shu.
Front Immunol, 2022 Mar 15; 13. PMID: 35281032    Free PMC article.
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
Milou Schuurbiers, Zhongyun Huang, +7 authors, Daniel Klass.
J Immunother Cancer, 2022 Feb 27; 10(2). PMID: 35217576    Free PMC article.
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
Ashley V DiMarco, Xiaodi Qin, +9 authors, James V Alvarez.
Cancer Immunol Res, 2021 Nov 20; 10(1). PMID: 34795033    Free PMC article.
Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Yanan Cui, Xinyin Liu, +4 authors, Renhua Guo.
Front Oncol, 2022 Apr 02; 12. PMID: 35359393    Free PMC article.
Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.
Xingjian Niu, Lei Yin, +7 authors, Hongfei Ji.
Cancer Sci, 2022 Feb 02; 113(4). PMID: 35102665    Free PMC article.
Resolving genetic heterogeneity in cancer.
Samra Turajlic, Andrea Sottoriva, Trevor Graham, Charles Swanton.
Nat Rev Genet, 2019 Mar 29; 20(7). PMID: 30918367
Highly Cited. Review.
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
Paolo A Ascierto, Lisa H Butterfield, +8 authors, Patrick Hwu.
J Transl Med, 2022 Apr 23; 20(1). PMID: 35449104    Free PMC article.
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.
Yue Li, Chong Li, +11 authors, Yuezhen Wang.
J Oncol, 2022 Apr 22; 2022. PMID: 35444698    Free PMC article.
Heterogeneity of the tumor immune microenvironment and its clinical relevance.
Qingzhu Jia, Aoyun Wang, +2 authors, Haixia Long.
Exp Hematol Oncol, 2022 Apr 25; 11(1). PMID: 35461288    Free PMC article.
Review.
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Smita S Chandran, Jiaqi Ma, +19 authors, Christopher A Klebanoff.
Nat Med, 2022 Apr 29; 28(5). PMID: 35484264    Free PMC article.
Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes.
Qian Liu, Jiali Lei, Xiaobo Zhang, Xiaosheng Wang.
Comput Struct Biotechnol J, 2022 May 03; 20. PMID: 35495113    Free PMC article.
A sheet pocket to prevent cross-contamination of formalin-fixed paraffin-embedded block for application in next generation sequencing.
Keiichi Iwaya, Hisae Arai, +6 authors, Masayoshi Soma.
PLoS One, 2022 May 05; 17(5). PMID: 35507545    Free PMC article.
Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.
Yanan Cui, Pengpeng Zhang, +7 authors, Renhua Guo.
Am J Cancer Res, 2022 May 10; 12(4). PMID: 35530271    Free PMC article.
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
Siming Li, Xiaowen Wu, +17 authors, Xinan Sheng.
J Immunother Cancer, 2022 Feb 24; 10(2). PMID: 35193932    Free PMC article.
A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.
Jie Peng, Lushan Xiao, Dan Zou, Lijie Han.
Front Med (Lausanne), 2022 May 21; 9. PMID: 35592856    Free PMC article.
Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample.
Rotem Katzir, Noam Rudberg, Keren Yizhak.
Nat Commun, 2022 Jun 03; 13(1). PMID: 35654823